Palatin Technologies, Inc.
Records under this name other than the patents Palatin Technologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 31 patents it holds.
Back to Palatin Technologies, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,727,990 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds Term ended Term ended May 21, 2026 · High confidence | Term ended | Term ended May 21, 2026 | High confidence |
| US 7,727,991 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds Term ended Term ended Jan 1, 2026 · High confidence | Term ended | Term ended Jan 1, 2026 | High confidence |
| US 8,580,746 | Amide linkage cyclic natriuretic peptide constructs Lapsed on the fee record Ended Nov 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 12, 2025 | From the USPTO record |
| US 8,580,747 | Cyclic natriuretic peptide constructs Lapsed on the fee record Ended Nov 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 12, 2025 | From the USPTO record |
| US 6,794,489 | Compositions and methods for treatment of sexual dysfunction Formerly held Term ended Term ended Nov 11, 2025 · From the USPTO record | Term ended | Term ended Nov 11, 2025 | From the USPTO record |
| US 7,732,451 | Naphthalene-Containing Melanocortin Receptor-Specific Small Molecule Term ended Term ended Aug 10, 2025 · Medium confidence | Term ended | Term ended Aug 10, 2025 | Medium confidence |
| US 7,235,625 | Multiple agent therapy for sexual dysfunction Term ended Term ended May 26, 2025 · From the USPTO record | Term ended | Term ended May 26, 2025 | From the USPTO record |
| US 7,718,802 | Substituted Melanocortin Receptor-Specific Piperazine Compounds Term ended Term ended Apr 16, 2025 · Medium confidence | Term ended | Term ended Apr 16, 2025 | Medium confidence |
| US 7,417,027 | Linear and cyclic melanocortin receptor-specific peptides Term ended Term ended Feb 1, 2024 · From the USPTO record | Term ended | Term ended Feb 1, 2024 | From the USPTO record |
| US 7,968,548 | Melanocortin Receptor-Specific Piperazine Compounds with Diamine Groups Lapsed on the fee record Ended Jun 28, 2023 · High confidence | Lapsed on the fee record | Ended Jun 28, 2023 | High confidence |